Neurocrine Biosciences
NBIX
#1371
Rank
S$20.08 B
Marketcap
S$201.41
Share price
0.84%
Change (1 day)
16.30%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): S$5.61

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is S$5.58. In 2024 the company made an earnings per share (EPS) of S$4.38 an increase over its 2023 EPS that were of S$3.29.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$5.6128.27%
2024S$4.3833.07%
2023S$3.2957.76%
2022S$2.0969.47%
2021S$1.23-78.21%
2020S$5.65990%
2019S$0.5281.82%
2018S$0.28-113.5%
2017S-$2.110.62%
2016S-$2.1057.28%
2015S-$1.3325.61%
2014S-$1.0618.84%
2013S-$0.89-1085.71%
2012S$0.09066

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Repligen
RGEN
S$0.03885-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.29-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
S-$79.00-1,515.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$26.57 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$1.75-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$2.23-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$2.21-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S-$2.63-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA